Germany, Austria, Switzerland
U.S.A., Canada
Together, let’s make medical innovation a reality for all.
Since 2003, Regen Lab SA has been committed to the development of a unique expertise for the design and manufacturing of high-quality medical devices, intended for cells therapies.
RegenPRP™ est un traitement médical qui utilise le plasma riche en plaquettes provenant du sang du patient pour améliorer et la régénération tissulaire.
Cellular Matrix® est un traitement innovant combinant le plasma riche en plaquettes (PRP) et l'acide hyaluronique pour améliorer la régénération tissulaire et la guérison.
RegenPRP™ combiné avec ATS (Autologous Thrombin Serum) est une approche avancée pour la régénération tissulaire qui utilise le plasma riche en plaquettes (PRP) enrichi en thrombine autologue pour maximiser les effets de guérison.
RegenExtracell est un traitement innovant axé sur la régénération tissulaire qui utilise une matrice extracellulaire enrichie en plasma riche en plaquettes (PRP).
L'acide hyaluronique est une substance naturellement présente dans le corps humain, particulièrement dans la peau, les articulations et les yeux.
Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.
Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.
Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.
As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.
WEBSITE PRIVACY NOTICE
We recommend you to acquaint yourself with the full content of our Privacy Policy.